About PMI

      Explore PMI’s global network

      At Philip Morris International (PMI), we have built a global network of affiliates, research facilities, smoke-free product production sites, and other locations where our colleagues work together toward a smoke-free future. Learn more about our global locations and some of their history. 

      There are 1,586 people, including scientists, engineers, technicians, and support staff  working in PMI R&D as of 2023.* Our colleagues come from all regions of the world, led by our headquarters located in Stamford, Connecticut, U.S., and our Operations Center in Lausanne, Switzerland. 

      Complementing the Cube, PMI’s R&D center in Neuchâtel, Switzerland, we have a global network of Philip Morris R&D facilities in Yerevan, Armenia; Bologna, Italy; Hong Kong and Shenzhen, China. These facilities not only contribute to our own research but also help develop and expand innovation in local areas. 

      Our global manufacturing network comprises 50 facilities, with 16 specifically dedicated to producing smoke-free products. From these facilities, we deliver technical expertise across the world. 

      Zoom in and explore the map below to learn more about each of our locations around the world.

      * Data includes employees of Swedish Match and Vectura Fertin Pharma.

      Related articles

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.